Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)

Author(s): Atsuo Takashima, MD¹; Tetsuya Hamaguchi, MD²; Junki Mizusawa, PhD³; Fumio Nagashima, MD⁴; Masahiko Ando, MD⁵; Hitoshi Ojima, MD⁶; Tadamichi Denda, MD⁷; Jun Watanabe, MD⁸; Katsunori Shinozaki, MD⁹; Hideo Baba, MD¹⁰; Masako Asayama, MD¹¹; Seiji Hasegawa, MD¹²; Toshiki Masuishi, MD¹³; Ken Nakata, MD¹⁴; Shunsuke Tsukamoto, MD¹⁵; Hiroshi Katayama, MD³; Kenichi Nakamura, MD³; Haruhiko Fukud, MD³; Yukihide Kanemitsu, MD¹⁵; Yasuhiro Shimada, MD¹⁶

Source: https://doi.org/10.1200/JCO.23.02722

Dr. Anjan Patel's Thoughts

This Japanese study showed no benefit with the addition of oxaliplatin to fluoropyrimidine plus bevacizumab (5FU+bev) in patients who were aged 70-74 but unfit, or >=75. Interestingly survival was actually shorter in the patients who received oxaliplatin at 21.3 vs 19.7 months.

PURPOSE

Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding OX to FP plus BEV (FP + BEV) remains unclear for older patients, a population for whom FP + BEV is standard. We aimed to confirm the superiority of adding OX to FP + BEV for this population.

METHODS

This open-label, randomized, phase III trial was conducted at 42 institutions in Japan. Patients with unresectable MCRC age 70-74 years with Eastern Cooperative Oncology Group performance status (ECOG-PS) 2 and those 75 years and older with ECOG-PS 0-2 were randomly assigned (1:1) to an FP + BEV arm or an OX addition (FP + BEV + OX) arm. Fluorouracil plus levofolinate calcium or capecitabine was declared before enrollment. The primary end point was progression-free survival (PFS). The study was registered in the Japan Registry of Clinical Trials (identifier: jRCTs031180145).

RESULTS

Between September 2012 and March 2019, 251 patients were randomly assigned to the FP + BEV arm (n = 125) and the FP + BEV + OX arm (n = 126). The median age was 80 and 79 years in the respective arm. The median PFS was 9.4 months (95% CI, 8.3 to 10.3) in the FP + BEV arm and 10.0 months (9.0 to 11.2) in the FP + BEV + OX arm (hazard ratio [HR], 0.84 [90.5% CI, 0.67 to 1.04]; one-sided P = .086). The median overall survival was 21.3 months (18.7 to 24.3) in the FP + BEV arm and 19.7 months (15.5 to 25.5) in the FP + BEV + OX arm (HR, 1.05 [0.81 to 1.37]). The proportion of any grade ≥3 adverse events was higher in the FP + BEV + OX arm (52% v 69%). There was one treatment-related death in the FP + BEV arm and three in the FP + BEV + OX arm.

CONCLUSION

No benefit of adding OX to FP + BEV as first-line treatment was demonstrated in older patients with MCRC. FP + BEV is recommended for this population.

Author Affiliations

¹Department of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan; ²Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama, Japan; ³JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan; ⁴Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan; ⁵Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; ⁶Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan; ⁷Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan; ⁸Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan; ⁹Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan; ¹⁰Department of Gastroenterology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; ¹¹Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan; ¹²Department of Clinical Oncology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan; ¹³Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; ¹⁴Department of Colorectal Surgery, Sakai City Medical Center, Osaka, Japan; ¹⁵Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan; ¹⁶Department of Clinical Oncology, Kochi Health Sciences Center, Kochi, Japan

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Here is a large phase-III well done study confirming what we knew from earlier studies, that ipilimumab plus nivolumab (Ipi+Nivo) is highly active and effective in the microsatellite instability-high metastatic colorectal cancer (MSI-high met-CRC) population. This is most likely more effective than single agent IO therapy but with higher rates of toxicity. When all things are equal, I would consider this to be the standard of care (SOC) in this context.

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Overall survival (OS) improvement was not statistically significant in the study arm but is a non-chemotherapy option. Patients here had tumors with MSS.

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study

Less maintenance is NOT NON-inferior, so it is inferior in patients with wild type BRAF metastatic colon cancer. So it is better to keep on the full regimen. Although, quality of life is better.

A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening

Colorectal cancer screening by peripheral blood testing? This cell-free DNA assay had an 83% sensitivity and 90% specificity for advanced neoplasia. However, the issue is that this does not detect precancerous lesions well. Colonoscopy has its obvious advantages as it can both diagnose colorectal cancer as well as eradicate precancerous lesions.

MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial

This is a nice, practical study showing that when considering liver directed therapy, options in metastatic CRC, CT’s alone are insufficient and contrasted MRI can be helpful. More than 30% of patients had care that was impacted using MRI prior to any therapeutic decisions.